Nessan Bermingham

D2B3 is a pre-clinical biotechnology company dedicated to advancing drug delivery solutions to the brain and central nervous system. Its proprietary technology allows to transiently and specifically open the blood brain barrier for therapeutic targeting of CNS diseases with high efficacy. Our approach is plug-and-play and works with most drugs and therapeutic classes.

At Excelsior Sciences we are revolutionizing small molecule innovation by developing a new form of chemistry that machines can do and AI can use to accelerate the discovery and manufacture of small molecules. Our unique smart blocc approach quickly creates molecular solutions from automated synthesis-friendly, function-infused and AI-readable building blocks. These smart bloccs serve as tokens in a modular chemical “language” that enables AI to accelerate discovery and manufacturing, derive novel insights and define new functional frontiers for an array of industries and applications. We are the only company built on a proven, published track record of making real-world advances in multiple fields using automated small molecule synthesis coupled with AI, with the goal to spark an innovation renaissance of safer, more effective and more sustainable solutions to human and planetary challenges.

Amide Technologies offers on-demand complex peptide manufacturing at unprecedented speed. Through its novel manufacturing platform developed at MIT, Amide is bridging the gap between traditional solid phase peptide synthesis and biological expression, empowering scientists on the cutting edge of peptide drug design.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.

Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company’s approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

EveryONE Medicines is committed to developing individualized precision medicines targeting genetic variants causing fatal, neurodegenerative diseases unique to just a few or even ONE patient. Momentum is building as technological advances with genomic testing and the prevalence of testing is improving rapidly to identify the rarest of rare mutations. Through a collaborative effort across all stakeholders in the treatment and diagnosis of rare genetic disease, EveryONE Medicines will bring a scalable solution to meet the needs of the individual patient who currently has limited hope.

Today, the biggest bottleneck in genetic medicine isn’t the power of mRNA, CRISPR, or gene therapy—it’s that we can’t get these medicines anywhere but the liver. Our RAPTOR™ platform is the first AI-driven system that makes extrahepatic genetic medicine scalable. Unlike the slow, inefficient trial-and-error process that dominates biotech, we directly test hundreds of novel lipid nanoparticles (LNPs) in non-human primates (NHPs) at 100 times lower cost, generating real-world, human-relevant data.

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology.

D2B3 is a pre-clinical biotechnology company dedicated to advancing drug delivery solutions to the brain and central nervous system. Its proprietary technology allows to transiently and specifically open the blood brain barrier for therapeutic targeting of CNS diseases with high efficacy. Our approach is plug-and-play and works with most drugs and therapeutic classes.

BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org

At Excelsior Sciences we are revolutionizing small molecule innovation by developing a new form of chemistry that machines can do and AI can use to accelerate the discovery and manufacture of small molecules. Our unique smart blocc approach quickly creates molecular solutions from automated synthesis-friendly, function-infused and AI-readable building blocks. These smart bloccs serve as tokens in a modular chemical “language” that enables AI to accelerate discovery and manufacturing, derive novel insights and define new functional frontiers for an array of industries and applications. We are the only company built on a proven, published track record of making real-world advances in multiple fields using automated small molecule synthesis coupled with AI, with the goal to spark an innovation renaissance of safer, more effective and more sustainable solutions to human and planetary challenges.

Amide Technologies offers on-demand complex peptide manufacturing at unprecedented speed. Through its novel manufacturing platform developed at MIT, Amide is bridging the gap between traditional solid phase peptide synthesis and biological expression, empowering scientists on the cutting edge of peptide drug design.

Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.